The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.
The number of new HIV cases diagnosed annually in Cyprus has been on the rise since 2005: more than 50 new cases of HIV were diagnosed every year from 2011 to 2013. This report addresses this issue and provides options on how Cyprus can respond to the epidemic.
This protocol for harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter from human isolates aims to increase the quality and comparability of antimicrobial resistance data collected at the EU level from different Member States. It is primarily targeted to the National Public Health Reference Laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.
This response plan is designed to prevent the spread of multidrug-resistant Neisseria gonorrhoeae (MDR NG) in the EU/EEA in the context of the possible emergence of untreatable gonorrhoea